Page 110 - Read Online

Cadamuro et al. Hepatoma Res 2022;8:11 https://dx.doi.org/10.20517/2394-5079.2021.140 Page 15 of 16

87. Jalalvand M, Darbeheshti F, Rezaei N. Immune checkpoint inhibitors: review of the existing evidence and challenges in breast
cancer. Immunotherapy 2021;13:587-603. DOI PubMed
88. Zeng FL, Chen JF. Application of immune checkpoint inhibitors in the treatment of cholangiocarcinoma. Technol Cancer Res Treat
2021;20:15330338211039952. DOI PubMed PMC
89. Xu G, Sun L, Li Y, et al. The clinicopathological and prognostic value of PD-L1 expression in cholangiocarcinoma: a meta-analysis.
Front Oncol 2019;9:897. DOI PubMed PMC
90. Xie Q, Wang L, Zheng S. Prognostic and clinicopathological significance of PD-L1 in patients with cholangiocarcinoma: a meta-
analysis. Dis Markers 2020;2020:1817931. DOI PubMed PMC
91. Tian L, Ma J, Ma L, et al. PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome. World J
Surg Oncol 2020;18:303. DOI PubMed PMC
92. Ma K, Wei X, Dong D, Wu Y, Geng Q, Li E. PD-L1 and PD-1 expression correlate with prognosis in extrahepatic
cholangiocarcinoma. Oncol Lett 2017;14:250-6. DOI PubMed PMC
93. Lim YJ, Koh J, Kim K, et al. Clinical implications of cytotoxic T lymphocyte antigen-4 expression on tumor cells and tumor-
infiltrating lymphocytes in extrahepatic bile duct cancer patients undergoing surgery plus adjuvant chemoradiotherapy. Target Oncol
2017;12:211-8. DOI PubMed
94. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015;348:74-80. DOI PubMed
95. Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol 2012;3:51. DOI
PubMed PMC
96. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev
Immunol 2012;12:239-52. DOI PubMed PMC
97. Ghidini M, Cascione L, Carotenuto P, et al. Characterisation of the immune-related transcriptome in resected biliary tract cancers.
Eur J Cancer 2017;86:158-65. DOI PubMed PMC
98. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science
2017;357:409-13. DOI PubMed PMC
99. Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary
tract cancer. JAMA Oncol 2020;6:888-94. DOI PubMed PMC
100. Klein O, Kee D, Nagrial A, et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced
biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial. JAMA Oncol 2020;6:1405-9. DOI PubMed PMC
101. Lin J, Yang X, Long J, et al. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary
tract carcinoma. Hepatobiliary Surg Nutr 2020;9:414-24. DOI PubMed PMC
102. Arkenau HT, Martin-Liberal J, Calvo E, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or
metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF). Oncologist 2018;23:1407-e136. DOI PubMed
PMC
103. Job S, Rapoud D, Dos Santos A, et al. Identification of four immune subtypes characterized by distinct composition and functions of
tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology 2020;72:965-81. DOI PubMed PMC
104. Yamamoto K, Ueno T, Kawaoka T, et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer.
Anticancer Res 2005;25:3575-9. PubMed
105. Lepisto AJ, Moser AJ, Zeh H, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant
therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008;6:955-64. PubMed PMC
106. Kaida M, Morita-Hoshi Y, Soeda A, et al. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination
therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother 2011;34:92-9. DOI PubMed
107. Higuchi R, Yamamoto M, Hatori T, Shimizu K, Imai K, Takasaki K. Intrahepatic cholangiocarcinoma with lymph node metastasis
successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case. Surg Today
2006;36:559-62. DOI PubMed
108. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Science 2014;344:641-5. DOI PubMed PMC
109. Feng KC, Guo YL, Liu Y, et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T
cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol 2017;10:4. DOI PubMed PMC
110. Guo Y, Feng K, Liu Y, et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced
biliary tract cancers. Clin Cancer Res 2018;24:1277-86. DOI PubMed
111. Feng K, Liu Y, Guo Y, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary
tract cancers and pancreatic cancers. Protein Cell 2018;9:838-47. DOI PubMed PMC
112. Sangsuwannukul T, Supimon K, Sujjitjoon J, et al. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells
targeting CD133 against cholangiocarcinoma cells. Int Immunopharmacol 2020;89:107069. DOI PubMed
113. Supimon K, Sangsuwannukul T, Sujjitjoon J, et al. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of
cholangiocarcinoma. Sci Rep 2021;11:6276. DOI PubMed PMC
114. Phanthaphol N, Somboonpatarakun C, Suwanchiwasiri K, et al. Chimeric antigen receptor T cells targeting integrin αvβ6 expressed
on cholangiocarcinoma cells. Front Oncol 2021;11:657868. DOI PubMed PMC
115. Cillo U, Fondevila C, Donadon M, et al. Surgery for cholangiocarcinoma. Liver Int 2019;39 Suppl 1:143-55. DOI PubMed PMC
116. Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have
different outcomes. Gastroenterology 2013;144:829-40. DOI PubMed PMC